연구성과로 돌아가기
2024 연구성과별 연구자 정보 (846 / 2344)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptorepositive metastatic breast cancer in DESTINY-Breast04 | Niikura, N. | Niikura, N | 2 | Tokai Univ, Sch Med, Dept Breast Oncol, Hiratsuka, Kanagawa, Japan | ||||||
| Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptorepositive metastatic breast cancer in DESTINY-Breast04 | Yamashita, T. | Yamashita, T | 3 | Kanagawa Canc Ctr, Dept Breast & Endocrine Surg & Oncol, Yokohama, Kanagawa, Japan | ||||||
| Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptorepositive metastatic breast cancer in DESTINY-Breast04 | Jacot, W. | Jacot, W | 4 | Inst Canc Montpellier, Dept Med Oncol, Montpellier, France | ||||||
| Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptorepositive metastatic breast cancer in DESTINY-Breast04 | Cameron, D. A. | Cameron, DA | 5 | Univ Edinburgh, Edinburgh Univ Canc Ctr, Western Gen Hosp, Dept Inst Genet & Canc, Edinburgh, Midlothian, Scotland | C-7781-2013 | Cameron, David | ||||
| Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptorepositive metastatic breast cancer in DESTINY-Breast04 | Tsurutani, J. | Tsurutani, J | 6 | Showa Univ, Adv Canc Translat Res Inst, Tokyo, Japan | ||||||
| Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptorepositive metastatic breast cancer in DESTINY-Breast04 | Sohn, J. | Sohn, J | 7 | Yonsei Univ, Coll Med, Severance Hosp, Dept Med Oncol, Seoul, South Korea | ||||||
| Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptorepositive metastatic breast cancer in DESTINY-Breast04 | Tokunaga, E. | Tokunaga, E | 8 | NHO Kyushu Canc Ctr, Dept Breast Oncol, Fukuoka, Japan | ||||||
| Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptorepositive metastatic breast cancer in DESTINY-Breast04 | Vidal Losada, M. J. | Losada, MJV | 9 | Hosp Clin Barcelona, Dept Med, Barcelona, Spain | AAJ-8633-2021 | Losada, Maria | ||||
| Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptorepositive metastatic breast cancer in DESTINY-Breast04 | Park, Y. H. | Park, YH | 10 | Samsung Med Ctr, Dept Hematol Oncol, Seoul, South Korea | ||||||
| Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptorepositive metastatic breast cancer in DESTINY-Breast04 | Lee, K. S. | Lee, KS | 11 | Natl Canc Ctr, Ctr Breast Canc, Goyang, South Korea | ||||||
| Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptorepositive metastatic breast cancer in DESTINY-Breast04 | Chae, Y. S. | Chae, YS | 12 | Kyungpook Natl Univ, Sch Med, Chilgok Hosp, Dept Oncol, Daegu, South Korea | ||||||
| Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptorepositive metastatic breast cancer in DESTINY-Breast04 | Prat, A. | Prat, A | 13 | August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapies Grp, Barcelona, Spain | ||||||
| Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptorepositive metastatic breast cancer in DESTINY-Breast04 | Suto, F. | Suto, F | 14 | Daiichi Sankyo Inc, Dept Translat Sci, Basking Ridge, NJ USA | ||||||
| Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptorepositive metastatic breast cancer in DESTINY-Breast04 | Kuwahara, Y. | Kuwahara, Y | 15 | Daiichi Sankyo Inc, Dept Translat Sci, Basking Ridge, NJ USA | ||||||
| Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptorepositive metastatic breast cancer in DESTINY-Breast04 | Boran, A. D. | Boran, AD | 16 | Daiichi Sankyo Inc, Dept Translat Sci, Basking Ridge, NJ USA |
페이지 이동: